Biovail ( BVF) acquired the U.S. rights to Ativan and Isordil from Wyeth ( WYE) for $130 million and annual payments related to a three-year supply agreement.

Sales of Ativan and Isordil in the U.S. exceeded $50 million in 2002.

Ativan is a benzodiazepine, indicated for managing anxiety disorders. The market for anxiety treatments reached more than $11 billion in 2002.

Isordil is a nitrate designed to prevent angina pectoris due to coronary artery disease. Sales of nitrate products were above $360 million last year.

"The acquisition of Ativan and Isordil is another example of the execution of Biovail's business model," the pharmaceutical company said in a press release. "These products have tremendous brand equity and strategically complement two of the company's target therapeutic areas."

Shares of Biovail were rising 3.4% to $48.22 in recent New York Stock Exchange trading. Wyeth was down 16 cents at $43.69.

If you liked this article you might like

Spain to Play Netherlands for World Cup

Spain to Play Netherlands for World Cup

Wal-Mart: Analysts' Upgrades, Downgrades

Wal-Mart: Analysts' Upgrades, Downgrades

Netherlands Advances to World Cup Final

Netherlands Advances to World Cup Final

Apple: Analysts' Upgrades, Downgrades

Apple: Analysts' Upgrades, Downgrades

World Markets Mostly Lower Monday

World Markets Mostly Lower Monday